Hepatic Cell News Volume 5.04 | Feb 5 2021

    0
    31







    2021-02-05 | HCN 5.04


    Hepatic Cell News by STEMCELL Technologies
    Vol. 5.04 – 5 February, 2021
    TOP STORY

    Targeting Tumor Lineage Plasticity in Hepatocellular Carcinoma Using an Anti-CLDN6 Antibody-Drug Conjugate

    The authors investigated the transmembrane tight junction protein Claudin6 (CLDN6) as a therapeutic target related to lineage plasticity for hepatocellular carcinoma.
    [Science Translational Medicine]

    Abstract
    Guide to everything you need to know about cell separation.
    PUBLICATIONSRanked by the impact factor of the journal

    PRMT6 Methylation of RCC1 Regulates Mitosis, Tumorigenicity, and Radiation Response of Glioblastoma Stem Cells

    The authors report that protein arginine methyltransferase (PRMT) 6 activity is required for the proliferation, stem-like properties, and tumorigenicity of glioblastoma stem cells, a subpopulation in glioblastoma critical for malignancy.
    [Molecular Cell]

    AbstractGraphical Abstract

    Nrf2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications

    Public hepatocellular carcinoma (HCC) datasets were assessed for concomitant presence of CTNNB1 mutations and either mutations in NFE2L2 or KEAP1, or Nrf2 activation by gene signature.
    [Hepatology]

    Abstract

    LncRNA UCID Promotes Hepatocellular Carcinoma Metastasis via Stabilization of Snail

    Lnc-UCID expression was quantified in hepatocellular carcinoma (HCC) tissues and HCC cell lines by qRT-PCR. HCC cell lines with lnc-UCID knockdown were established by lentivirus transduction.
    [Oncotargets and Therapy]

    Full Article

    Functional Proliferating Human Hepatocytes: In Vitro Hepatocyte Model for Drug Metabolism, Excretion and Toxicity

    Proliferating primary human hepatocytes (PHH) generated from multiple PHH donors were expanded more than 200 folds within four passages, partially maintained their metabolic or transporter capacities, and were able to regain their mature hepatic property after 3D culture.
    [Drug Metabolism and Disposition]

    AbstractFull Article

    The Fucose-Specific Lectin ANL from Aspergillus niger Possesses Anti-Cancer Activity by Inducing the Intrinsic Apoptosis Pathway in Hepatocellular and Colon Cancer Cells

    Researchers observed that Aspergillus niger strongly bound to both HepG2 and HT‐29 cell‐lines and this interaction was effectively blocked with L‐fucose and mucin in a dose and time‐dependent manner with an IC50 of 1.25 and 5μg/mL for HepG2 and HT‐29 cells respectively at 48 hours.
    [Cell Biochemistry and Function]

    Abstract

    Functional Interaction between Macrophages and Hepatocytes Dictate the Outcome of Liver Fibrosis

    While hepatocyte-specific c-jun deletion led to increased fibrosis, the opposite outcome was observed when c-jun was deleted in both hepatocytes and Kupffer cells.
    [Life Science Alliance]

    Abstract

    In this webinar on hepatic organoids review the biological characteristics and practical considerations of adding organoids to your research.
    REVIEWS

    Combined Hepatocellular-Cholangiocarcinoma: An Update

    Increasing molecular evidence supports the clonal nature of combined hepatocellular-cholangiocarcinoma (CCA) and molecular profile parallels its biphenotypic histological appearance, with genetic alterations that are classically observed in hepatocellular carcinoma and/or intrahepatic CCA.
    [Journal of Hepatology]

    Abstract

    ZEB1 Serves an Oncogenic Role in the Tumorigenesis of HCC by Promoting Cell Proliferation, Migration, and Inhibiting Apoptosis via Wnt/β-Catenin Signaling Pathway

    EB1 could promote the proliferation, migration, and invasion of hepatocellular carcinoma cells. On the downstream regulation mechanism, ZEB1 could activate the Wnt/β-catenin signaling pathway by upregulating the protein expression levels of β-catenin, c-Myc, and cyclin D1.
    [Acta Pharmacologica Sinica]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    VBI Vaccines Announces US FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine

    VBI Vaccines, Inc. announced that the FDA has accepted its filing of the Biologics License Application for the company’s 3-antigen prophylactic hepatitis B vaccine candidate for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.
    [VBI Vaccines, Inc.]

    Press Release
    FEATURED EVENT

    Wisconsin Stem Cell Symposium: The Single Cell Revolution in Stem Cells

    April 14, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Senior Researcher – Translational Cell Assays

    Karolinska Institutet – Stockholm, Sweden

    Research Associate – Development of Fatty Liver Disease and Fibrosis

    University of Connecticut – Storrs, Connecticut, United States

    Assistant Professor – Pediatric Hepatologist

    BC Children’s Hospital – Vancouver, British Columbia, Canada

    Postdoctoral Fellow – Tumor Biology and Therapeutic Applications

    Harvard Medical School – Boston, Massachusetts, United States

    Image Analysis Specialist – Cancer and Chronic Diseases

    Novo Nordisk – Copenhagen, Denmark

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hepatic Cell News Twitter